Dedicated to the Global Collection and Distribution of Multiple Sclerosis Information. Providing for all affected by MS, via the internet and live seminars. Visit www.msviewsandnews.org
ABOUT this BLOG and How to use it
Thursday, April 30, 2009
Merck says oral multiple-sclerosis drug effective
By Thomas Gryta
Last update: 9:35 p.m. EDT April 29, 2009
NEW YORK (MarketWatch) -- Merck KGaA reported late-stage data showing that its cladribine tablets significantly cut the rate of clinical relapses, disability progression and brain lesions in patients suffering from relapsing remitting multiple sclerosis, echoing preliminary data reported earlier this year.
But a handful of cancer cases in the study may raise some safety concerns for physicians that must choose cladribine over alternative therapies that have longer safety data in larger patient populations.
What is your opinion on the Oral Therapies? Please comment with a reply.
============================================
| Reactions: |
Wednesday, April 29, 2009
MS Views and News Website's (basic) Tutorial
A Basic Tutorial of the MS Views and News websiteReviewing each of the links found below, will make
navigation of the website that much more, user friendly.
Below are the links from our Main Menu and our Resources Menu
Updates & many new items are added weekly
Main Menu
- Home - Website's Homepage
- Stu's 'MS' Blog - Save/bookmark for daily viewing
- Library of MS Archives - Use search box to find MS topics to learn
- MS Topics of interest
- Register for e-Newsletter & site - register to receive our weekly MS e-Newsletter
- Mission Statement
- Disclaimer / and Terms of Use
- Post Message To Guestbook - Must be a registered member of site to post comments
- Contacts
Resources
- Achieving Wellness
- Ask the MS Nurse - stories written by an MS RN w/MS
- MS Resource Web Links - Links to global organizations
- MS Video Library
- Occupational Therapy - stories written by an Occupational Therapist
If you have any questions, write to: stuart@msviewsandnews.org
============================================
| Reactions: |
"Good Cholesterol" May Help Decrease Multiple Sclerosis Inflammation, Lessen Disability
source: University of Buffalo
BUFFALO, N.Y. -- Could HDL, the "good cholesterol," have the same protective effect in multiple sclerosis, an inflammatory disease of the brain's white matter, as it does in heart disease, through its anti-inflammatory effects on blood vessels?
The answer may be yes, based on results of research conducted at the University at Buffalo and presented today (Tuesday, April 28) in a poster session at the American Association of Neurology meeting in Seattle, Wash.
Allison S. Drake, MSc, a researcher in the Jacobs Neurological Institute (JNI), UB's Department of Neurology, is first author on the study.
Bianca Weinstock-Guttman, M.D., UB associate professor of neurology and director of the JNI's Baird Multiple Sclerosis Center, initiated and oversaw the research.
PLEASE return here to leave comments - thank you
| Reactions: |
For those in South Florida, to know of Locally enrolling MS Studies
CURRENT ENROLLING STUDIES
- Primary Progressive MS - A 5-year study comparing the efficacy and safety of oral Fingolimod versus placebo. For more information visit: http://www.msclinicaltrials.com/.
- Primary Progressive or Relapsing- Remitting MS – A 14-week study comparing safety & Efficacy of 3 different does of oral Nerispirdine versus placebo in the treatment of walking disability. Must be able to walk 25 feet in a designated time frame.
- Relapsing-Remitting MS - A 2 year study comparing safety and efficacy of 2 different doses of oral Fumarate versus placebo with Copaxone as an active comparator. For more information visit: www.clinicaltrials.gov/ct/show/NCT00451451.
- Relapsing Remitting MS - A 5 1/2-year study comparing safety and efficacy of intravenous Alemtuzumab (Campath) versus 3 times weekly subcutaneous Interferon Beta-1a (Rebif). For more information visit: www.clinicaltrials.gov/ct2/show/NCT 005488405.
- ENROLLING SOON: Relapsing-Remitting MS – A 6-month study comparing the safety & efficacy of MRI lesions on 3 doses BAF312 Hemifumarate verses placebo.
| Reactions: |
New Neura.net podcasts including one on Pediatric MS
![]() | Listen to the latest podcasts! – Two new NeuraPod podcasts are now available for listening or downloading. NeuraPod podcasts are also available on iTunes. | ||||
|
Be sure to visit Neura.net for the latest issues of
informative newsletters and programs for you and
your patients. Below are the latest additions to the
site.
============================================
| Reactions: |
Research Shows Plasma Exchange Helps Multiple Sclerosis Patients
Aurora St. Luke's Team Sees Lives Changed for the Better with Plasma Exchange.
"There is no other treatment that brings about such a reversal in multiple sclerosis," says
Over 25 years, Dr. Khatri and his team followed 271 patients with chronic and progressive multiple sclerosis. These patients had not responded to drug therapy and were experiencing an increasing decline in their motor and verbal abilities. Patients received weekly plasma exchange treatments for 10 weeks, with the pace of plasma exchange therapy slowing over time or as their condition improved.
Out of 271 patients, 217 or 80 percent, saw a long-term improvement in their disability.
Unlike conventional multiple sclerosis treatments, such as chemotherapy drugs, which can have serious side effects such as heart damage or leukemia, the plasma exchange therapy was found to be safe, with no serious side effects.
Continue reading this PRNewswire story from Aurora Healthcare.
Have a Question, Comment or information for others? If so, please use the post comment link found below. Your name and email address would be appreciated but is not necessary unless you want a response from others. Thank You
============================================
| Reactions: |
Novartis MS drug (FTY720) effective but safety an issue
By Emma Thomasson
ZURICH, April 29 (Reuters) - Novartis AG (NOVN.VX) said 80-83 percent of those taking its multiple sclerosis drug FTY720 are relapse-free compared with 69 percent on the leading current treatment, but it reported a new patient death.
Novartis said the patient died from aspiration pneumonia related to a progressive neurological condition.
Safety concerns have surrounded the drug for some time.
FTY720, has been associated with potentially fatal infections, skin cancer and a case of hemorrhaging focal encephalitis, an inflammation of the brain with bleeding. It is unclear whether the drug was responsible for the events.
Continue reading from Reuters.com
Have a Question, Comment or information for others? If so, please use the post comment link found below. Your name and email address would be appreciated but is not necessary unless you want a response from others. Thank You
============================================
| Reactions: |
Syndicated "Live Journal" Feed for Stu's Views and M.S. News
I am new to this syndication "stuff".. Yes, I too need to learn. And so, when I was visiting with the MS Foundation the other day we were chatting of and about my e-newsletter and MS blog. Kasey, with whom I was speaking, mentioned that she would create a Live Journal Feed and then when I check a link she sent me http://msf-staff.livejournal.com/7267.html - I found what she wrote.
Then Kasey provided me, via email, something for me to provide to each of you, who want to receive the Stu's Views & MS News livejournal feed:
Your syndicated feed (which livejournal bloggers can add to their friend's list and see daily) is http://syndicated.livejournal.com/msviews/.
So, I hope that some of you, who have interest, learn how to create and use this live journal feed
and then help to educate me and others on it's benefits...
My thanks to Kasey of the MSF for getting me and Stu's BViews and M.S. News, hooked-up with this Live Journal feed...
Leave comments if you wish. Thank You
============================================
| Reactions: |
MS Drug News, MS Risk Factors Create Headlines From American Academy Of Neurology Meeting This Week
The annual meeting of the American Academy of Neurology (AAN) is being held April 25th-May 2nd in Seattle. There will be hundreds of presentations related to MS, including news on MS drugs in the pipeline or now in use, as well as factors such as smoking that may increase the risk of getting MS.
As usual, the National MS Society plans to cover the most significant studies being presented there in a comprehensive summary that will be posted after the meeting has taken place.
In the meantime, the scientific abstracts presented at the meeting are available on the AAN's Web site.
Source: National Multiple Scleroris Society
Article URL: http://www.medicalnewstoday.com/articles/147911.php
============================================
| Reactions: |
Tysabri may treat myelin sheath damage from MS
|
TUESDAY, April 28 (HealthDay News) -- The drug Tysabri (natalizumab) appears to regenerate and stabilize damage done to the myelin sheath in people with multiple sclerosis (MS), a study from drug makers Biogen Idec and Elan Corp shows.
MS is nervous system disease that affects the brain and spinal cord. Symptoms experienced by MS patients are caused by damage to the myelin sheath that surrounds and protects nerve cells.
In this study, researchers used advanced MRI technology to measure lesions and normal brain tissue in patients who took either Tysabri, interferon beta-1a, or no drugs. After 12 months of follow-up, the 62 patients who took Tysabri showed remyelination when compared to the 26 who took inteferon beta-1a or the 22 patients in the control group.
The findings were presented Tuesday at the annual meeting of the American Academy of Neurology, in Seattle.
"What we have seen in these MRI data suggest that Tysabri may have the capacity to repair and possibly restore some of the damaged myelin sheath that protects nerve fibers. Results from this study support the continued investigation of the potential effects of Tysabri on this process," lead investigator Dr. Robert Zivadinov, of the Jacobs Neurological Institute in Buffalo, N.Y., said in a news release.
Tysabri is approved for treatment of relapsing forms of MS in the United States and for relapsing-remitting MS in the European Union.
-- Robert Preidt
SOURCE: American Academy of Neurology, news release, April 28, 2009
Copyright © 2009 ScoutNews, LLC. All rights reserved.
============================================| Reactions: |
Julie’s Low Dose Naltrexone Journal: Week One
Tuesday April 28, 2009
The past week on low-dose naltrexone as a treatment for my multiple sclerosis (MS) has given me the opportunity to make many observations, which I will share with you. First, however, let me thank all of you who took the time to comment on my previous blogs and cheer me along. You have not only given me encouragement, but food for thought. It is a strange thing to be taking a drug that very few people know anything about in this formulation for this problem - we are the experts here, in many respects, and it is crucial that we share our impressions and experiences with each other.Overall, I think I am feeling better during the day. I have not, however, had that feeling of being a person without MS that I experienced on day 1, but looking at the big picture, it seems that fatigue is diminishing and I am getting more mileage out of my mornings before needing a nap.
Continue to read Julie's Story - CLICK THIS
============================================
| Reactions: |
In Recognition of MS World Day ...
To participate, call in directly (within the USA) at (888) 550-5602 and enter 2344 1168. Register to get a meeting reminder by emailing editor@msfocus.org or by calling (800) 225-6495, ext. 145.
Established by the Multiple Sclerosis International Federation, World MS Day will occur on the last Wednesday of May every year. For more information about World MS Day visit www.worldmsday.org.
Further notices of this event will be sent as we near the date...
============================================
| Reactions: |
MS-related Mobility Impairment Contributes to Reduction in Employment Status and Income Level
Greatest Changes in Income Level Due to Mobility Loss Occur Early On, as People with MS Transition from Normal Mobility to Minimal Mobility Impairment
HAWTHORNE, N.Y.--(BUSINESS WIRE)--Apr. 29, 2009-- People with multiple sclerosis (MS) experience reduced income and earning potential as their mobility impairment increases, according to data collected from more than 8,100 participants of the North American Research Committee on Multiple Sclerosis (NARCOMS) database, the largest self-reported MS patient registry in the world. The data were presented yesterday at the American Academy of Neurology (AAN) 61st Annual Meeting in Seattle, WA.
“Approximately half of people with MS will have mobility impairment within 15 years of their disease onset, and MS often affects people early in life during their most economically productive years. These data indicate that even minor mobility impairments contribute to the loss of productivity and income,” said Timothy L. Vollmer, M.D., Director of the NARCOMS Project and Professor, University of Colorado Health Sciences Center. “People with MS typically develop increasing mobility impairment as their disease progresses, which can significantly impact their socioeconomic status, affecting their ability to stay in the workforce and to provide for their families. Unfortunately, many people with MS are then at risk to lose access to company-sponsored healthcare.”
Have a Question, Comment or information for others? If so, please use the post comment link found below. Your name and email address would be appreciated but is not necessary unless you want a response from others. Thank You
============================================
| Reactions: |
Tuesday, April 28, 2009
Past environmental sun exposure and risk of multiple sclerosis: a role for the Cdx-2 Vitamin D receptor
Dickinson J, Perera D, van der Mei A, Ponsonby AL, Polanowski A, Thomson R, Taylor B, McKay J, Stankovich J, Dwyer T.Menzies Research Institute, University of Tasmania, Hobart, Tasmania, Australia Jo.Dickinson@utas.edu.au.
Multiple studies have provided evidence for an association between reduced sun exposure and increased risk of multiple sclerosis (MS), an association likely to be mediated, at least in part, by the vitamin D hormonal pathway. Herein, we examine whether the vitamin D receptor (VDR), an integral component of this pathway, influences MS risk in a population-based sample where winter sun exposure in early childhood has been found to be an important determinant of MS risk.
» Read More
.
Have a Question, Comment or information for others? If so, please use the post comment link found below. Your name and email address would be appreciated but is not necessary unless you want a response from others. Thank You
============================================
| Reactions: |
Long-Term Study with COPAXONE® Indicated Protective Effect on Brain Tissue in Multiple Sclerosis Patients
These six-year results augment previously published findings suggesting that treatment with COPAXONE® may provide a neuroprotective effect in RRMS patients1, 2.The study, "Six-Year Prospective Multi-Voxel Brain MRS Study of Two Cohorts in RRMS To Examine the Effect of Glatiramer Acetate on Neuronal/Axonal Metabolic Injury," is the largest (n=46) and longest study of its kind to date. In the study, patients taking COPAXONE® for six years experienced an improvement in neuronal mitochodrial function, as quantified by an increase in neuronal NAA levels and evaluated by 1H- Magnetic Resonance Spectroscopy (1H-MRS).
Continue to read this article direct from the Teva website
If you are not yet receiving the weekly MS related e-Newsletter, "Stu's Views and MS Related News", then please use this link to register. - thank you
============================================
| Reactions: |
New Data Illustrate Novel Mechanism of Action of Laquinimod, An Oral Compound For The Treatment of Multiple Sclerosis
Jerusalem, Israel, Lund, Sweden and Seattle, Washington, April 28, 2009 -
Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) and Active Biotech (NASDAQ OMX NORDIC: ACTI) today announced results from several new clinical and preclinical studies providing further insight on the immunomodulatory mechanism of action (MOA) of laquinimod, a novel oral once-daily compound being developed for the treatment of relapsing-remitting multiple sclerosis (RRMS).
Four sets of data being presented at the 61st Annual Meeting of the American Academy of Neurology (AAN) in Seattle stand to increase the understanding of how laquinimod may reduce multiple sclerosis (MS) activity and affect mechanisms related to disease pathology.While research looking at the mechanism by which the compound exerts its clinical effect is ongoing, currently available data indicate that laquinimod impacts RRMS by modulating key processes of the immune system, and suggest an immunomodulating effect within the central nervous system (CNS)."
As we continue to study how laquinimod impacts multiple sclerosis, we remain encouraged by the potential of this oral candidate," explains Scott Zamvil, M.D., Ph.D., Associate Professor, Department of Neurology, University of California, San Francisco. "Laquinimod, with a balanced safety and efficacy profile, may address a currently unmet medical need for patients seeking effective oral therapy for MS that is well tolerated and safe." Laquinimod recently received Fast Track designation from the U.S. Food and Drug Administration (FDA), which may allow the drug to enter the market as soon as late 2011. Teva completed enrollment for the first of its two Phase III clinical trials for laquinimod (ALLEGRO) in November 2008, and the second global Phase III study (BRAVO) is on schedule to complete patient enrollment in the first half of 2009.
Click here to continue to read from the TEVA website.
============================================
| Reactions: |
Ataxia and tremor edition of MS in focus now in Spanish and German
Many thanks to Dr Gabriele Seestaedt from the German MS Society (DMSG) and Sara Martinez-Pasamar from the Institute for Biomedical Research August Pi Sunyer (IDIBAPS), Hospital Clinic of Barcelona, Spain for their help checking the translations.
Please click here to download the Spanish edition and here for the German edition.
The English edition can also be downloaded and read online here, or for a free printed copy, please email info@msif.org.
Editor's Note (from Stuart) - for those that don't know the term Ataxia: Ataxia definition - Medical Dictionary definitions ..
============================================| Reactions: |
Monday, April 27, 2009
Opexa Publication Of Tovaxin(R) Clinical Data In Journal Of Clinical Immunology
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a company developing a novel T-cell therapy for multiple sclerosis (MS) and a stem cell therapy for diabetes, today announced that data from its Phase I/II dose escalation study has been recently published in the May 2009 edition of the prestigious Journal of Clinical Immunology. Encouraging data from this clinical study paved the way for the larger Phase IIb TERMS trial that was completed in late 2008.
This small dose finding study of Tovaxin®, Opexa's T cell vaccine in development for MS, enrolled patients with relapsing-remitting MS or secondary progressive MS who had failed or were intolerant of currently approved MS therapies. The study was designed to find a safe and effective Tovaxin dose.
Tovaxin immunization resulted in rapid depletion of circulating myelin-reactive T cells (MRTC), with an observed dose-response effect. A safe and effective dose was identified for further clinical trials, associated with reductions in MRTC ranging from 92% at week 5 to 65% at week 52. Clinically, using the per-protocol criteria for MS relapses, a statistically significant reduction in relapse rate (85%, p<0.05)
To read more from the Medical News Today article, click here.
.
Have a Question, Comment or information for others? If so, please use the post comment link found below. Your name and email address would be appreciated but is not necessary unless you want a response from others. Thank You
============================================
| Reactions: |
In the UK - It's Multiple Sclerosis Awareness Week from 27th April to 3rd May....
It's an opportunity to try and raise awareness about a condition that affects some 85,000 people in this country and about which there are many misconceptions.
Multiple Sclerosis can affect anyone, and international standard footballers are no different in this respect to distinctly average 5-a-side trundlers like me. One player affected will be familiar to many football fans of a certain age, and he is one who had his career at the highest level cruelly cut short by this presently incurable condition...
Click her to continue to read from: Cheer Up Alan Shearer.
If not yet registered to receive our weekly ms related e-newsletter, click here to register. Thank You
---------------------------------
| Reactions: |
Knowledgable information for those other-than, the MS patient - "WHAT MS Means":
Information for YOU ( the MS Patient) to provide to others around you...
Having MS means many things change, and a lot of them are invisible.
Unlike having cancer or being hurt in an accident, most people do not understand even a little about MS and it's effects on us; and many of those who think they do know are actually misinformed. In the spirit of informing those who wish to understand...
These are the things that I would like you to understand about me before you judge me:
Please understand that being sick does not mean I'm no longer a human being. I have to spend most of my day in considerable pain and exhaustion and if you visit I probably don't seem like much fun to be with, but I'm still me stuck inside this body. I still worry about school, and work, and my family and friends, and most of the time I'd still like to hear you
talk about yours too.
.
Have a Question, Comment or information for others? If so, please use the post comment link found below. Your name and email address would be appreciated but is not necessary unless you want a response from others. Thank You
============================================
| Reactions: |
From an MS Patient's perspective: What living with Multiple Sclerosis "feels like"
Information provided by Colleen, in Upstate NY. My thanks to Colleen for her contribution.
Because We don't Feel Well, - - Put yourself
in Our Shoes By Using The Examples of our Symptoms Below...
- Painful Heavy Legs: Apply Tightly 20 LB ankle weights and 15 LB thigh weights then take a 1 mile walk, clean the house, go shopping and then sit down - how ya' feeling now?
- Painful Feet: Put equal or unequal amounts of small pebbles in each shoe then take a walk, if we are mad at you we would prefer needles to pebbles.
- Loss of Feeling in Hands and/or Arms: Put on extra thick gloves and a heavy coat then try and pick up a pencil, if successful stab yourself in the arm. .
Have a Question, Comment or information for others? If so, please use the post comment link found below. Your name and email address would be appreciated but is not necessary unless you want a response from others. Thank You
============================================
| Reactions: |
CDC info on the Swine Flu
To Baylor CME Course Participants:
Enclosed in this message is a link to the CDC for current information and health care measures for clinicians, patients, and the public regarding swine influenza A (H1N1) and the newly identified cases in the United States. On the CDC site you can register for updates via email or
subscribe to RSS feeds to stay abreast of emerging information.
For Specific Information: http://www.cdc.gov/swineflu/investigation.htm
For General Information: http://www.cdc.gov/swineflu/
Yours truly,
Michael Fordis, MD
Director, Center for Collaborative and Interactive Technologies
Senior Associate Dean and Director, Office of Continuing Medical Education
Baylor College of Medicine
.
Have a Question, Comment or information for others? If so, please use the post comment link found below. Your name and email address would be appreciated but is not necessary unless you want a response from others. Thank You
============================================
| Reactions: |
Bharatbook.com : SWOT Analysis of Global Multiple Sclerosis Market 2009-2024
The multiple sclerosis (MS) market has total global revenues of over $6bn in 2008. Those revenues will exceed $9bn during the second half of next decade, our new study shows. The World Health Organization estimates that over 2.5 million people suffer from multiple sclerosis worldwide. The prevalence and onset of MS in children andadults is expected to rise steadily. Global sales for MS therapies will rise accordingly, due to epidemiological, healthcare and commercial drivers. In this new market-based study - The Global Multiple Sclerosis Market 2009-2024 - we show and explain those trends in detail. This report will provide you with the analytical information that you need to understand current trends and future directions in the MS market area, the successful drugs being introduced and where the future successful growth of the market lies.
( www.bharatbook.com/Market-Research-Reports/Repor .. )
The Global Multiple Sclerosis Market 2009-2024 commercially analyses both leading and emergent treatments, with key companies and products discussed comprehensively. In particular, we discuss prospects for the following MS drugs:
>> Click to continue to read from LIVE P-R
============================================
| Reactions: |
Interim CDC Guidance for Nonpharmaceutical Community Mitigation in Response to Human Infections with Swine Influenza
This document provides interim planning guidance for state, territorial, tribal, and local communities that focuses on several nonpharmaceutical measures that might be useful during this outbreak of swine influenza A (H1N1) virus aimed at reducing disease transmission and associated morbidity and mortality.
These recommendations are based on current information and are subject to change based on ongoing surveillance and continuous risk assessment.
Click:
Interim CDC Guidance for Nonpharmaceutical Community Mitigation in Response to Human Infections with Swine Influenza (H1N1) Virus
============================================
| Reactions: |
Sunday, April 26, 2009
Learn what MS Lifelines can do for you...
Become part of a community that shares ideas, strategies and support for living with relapsing MS.
An educational and supportive community for people living with multiple sclerosis.
What's New
- Experiencing a change of insurance? MS LifeLines Reimbursement Specialists are available Monday-Friday, 8 AM to 8 PM ET
- Your Questions Answered. Watch videos and read responses from MS experts and others
============================================
| Reactions: |
Saturday, April 25, 2009
Positive Multiple Sclerosis Data using Fat Stem Cells
By Medistem - Apr 24, 2009 -
(HealthNewsDigest.com) - San Diego, CA- Medistem Inc announced today publication of a peer reviewed paper describing the scientific rationale and preliminary results of three patients with multiple sclerosis treated with their own fat derived stem cells. (Pictured: Dr. Robert Harman CEO of Vet-Stem)
“In addition to our endometrial regenerative cell (ERC) universal donor stem cell technology, for which an IND has been filed, Medistem has been committed to developing a pipeline of therapeutic products, including in the area of immune modulation” Said Thomas Ichim, CEO of Medistem. “Given our previous observations and IP filings that a stem cell-rich component of adipose tissue, called the Stromal Vascular Fraction, can concurrently immune modulate, while inducing regenerative activities, we are pleased to see the clinical translation of this approach into multiple sclerosis patients.”
>> Continue reading directly from the Health News Digest website
.Have a Question, Comment or information for others? If so, please use the post comment link found below. Your name and email address would be appreciated but is not necessary unless you want a response from others. Thank You
============================================
| Reactions: |
Adult Stem Cells May Help Treat Multiple Sclerosis
By Todd Neale, Staff Writer, MedPage Today
Published: April 24, 2009
Reviewed by Dori F. Zaleznik, MD; Associate Clinical Professor of Medicine, Harvard Medical School, Boston.
"While obviously no conclusions in terms of therapeutic efficacy can be drawn from these reports," Dr. Minev said, "this first clinical use of fat stem cells for treatment of multiple sclerosis supports further investigations into this very simple and easily implementable treatment methodology."
No currently available treatment for multiple sclerosis selectively inhibits autoimmune destruction of the nervous system or stimulates regeneration of damaged myelin sheaths, according to the researchers.
>> Continue reading , direct from the medpage today article
Have a Question, Comment or information for others? If so, please use the post comment link found below. Your name and email address would be appreciated but is not necessary unless you want a response from others. Thank You
============================================
| Reactions: |
Friday, April 24, 2009
Landmark paper to guide neurologists through the complex process of distinguishing MS from other mimicking disorders
| National MS Society Research News for Research Advocates and RA Staff Liaisons |
| NEW INFORMATION POSTED ABOUT MULTIPLE SCLEROSIS We have just posted a bulletin on the national Web site (pasted below) announcing the publication of a landmark paper to guide neurologists through the complex process of distinguishing MS from other mimicking disorders (a process known as differential diagnosis).
Please share the "For Professionals" version (see links below) of this bulletin with your local healthcare professionals, especially your CAC and those on your Referrals List. |
The "For Professionals" bulletin is available as a PDF from the Intranet (in Research Section), or as a Web link: http://www.nationalmssociety.org/news/news-detail/index.aspx?nid=1308
Have a Question, Comment or information for others? If so, please use the post comment link found below. Your name and email address would be appreciated but is not necessary unless you want a response from others. Thank You
============================================
| Reactions: |
Cut your auto insurance bills in half -- A tip for some
Even without switching insurers, you might be able to slash what you're paying for coverage. Here are ways to cut your premium.
By Insure.com
If you're looking to trim your expenses as much as possible, you might be eyeing your insurance bills. There are several ways to tinker with your auto insurance coverage to chop your premium to a bare minimum.
Click here to learn how:
The above program is not endorsed by Stu's Views & MS News, but appears that it can be beneficial and cost effective for some...
============================================
| Reactions: |
Thursday, April 23, 2009
A UK Consensus On The Management Of The Bladder In Multiple Sclerosis
Medical News Today Thu, 23 Apr 2009
Bladder problems are a common and distressing aspect of multiple sclerosis. Their management is currently erratic in the UK, although the problems are highly amenable to treatment.
Click to read complete article:
A UK Consensus On The Management Of The Bladder In Multiple Sclerosis
Have a Question, Comment or information for others? If so, please use the post comment link found below. Your name and email address would be appreciated but is not necessary unless you want a response from others. Thank You
============================================
| Reactions: |
Dole Food Company owner David Murdock announced a partnership with the National MS Society
Dole Food Company owner David Murdock announced a partnership with the National MS Society to kick off a campaign for multiple sclerosis research at the North Carolina Research Campus.
click to read: Murdock announces campaign for MS research
.
| Reactions: |
"Dating for Disabled"
New Dating Site – designed specifically for you
Click Here for a free subscription
(See banner on right side of this page)
With the popularity of online dating, it’s likely that the majority of you have probably at least considered it at one point in time. But, with all of the choices out there, where do you start? You may consider the biggest dating pools (like match.com), but be advised that not everyone will be accepting of your challenge. In that case, there are several niche dating sites for people like you. In fact, Google “Dating for Disabled” and you will find thousands of listings. Look at them a bit more closely and what do you get? What is the value? Their promise to you?
The recent beta launch of Datebility.com provides a new dating community that offers a new promise, designed specifically for you. The community has all of the basics: profiles, email, search, flirt, match and more. That’s where the similarities end. Each aspect of the site focuses on enhancements for various disabilities and new web technologies that make finding a mate, or at least a date for Saturday night, fun and easy.
For example, your profile allows you to identify your disability (optional) and degree of independence. Your search preferences are the same. New web technologies have paved the way for video and audio chat and a socialize page where featured content, blogs, groups, and forums are all full of content related to your dating life. Even pictures allow you to present yourself in the most flattering ways by allowing cropping and descriptive titles.
While in Beta, Datebility.com is looking for your help and are rewarding you handsomely for doing so. Now is your opportunity to sign up for free and tell them what the site should be and how it can better serve your needs. Plus, if you sign up while they are still in Beta, they won’t charge you for the rest of 2009. Simply go to datebility.com and register. With your participation, this community will become an even more exciting online venue for meeting, dating, and social networking.
You can also look for datebility.com on the most recent issue of Chloe Magazine, as well as the top of Chloemagazine.com. They are also the sponsor of the 2009 Chloe Magazine Model Search and model receptions at each of this year’s Abilities Expo events, as they continue to support the disabled community. Also, keep checking Chloe Magazine and chloemagazine.com as we will be offering free memberships over the coming months.
Click Here for a free subscription
Published Press
Stew@datebility.com (877) 657.5571 x 703
=====================
| Reactions: |
Acorda Therapeutics Resubmits New Drug Application for Fampridine-SR
Date: 4/23/2009 - 6:00:00 AM
Click to review:Acorda Therapeutics Resubmits New Drug Application for Fampridine-SR for Improvement of Walking Ability in People with Multiple Sclerosis
Fampridine-SR is a novel therapy being developed to improve walking ability in people with multiple sclerosis (MS).
============================================
| Reactions: |
Wednesday, April 22, 2009
Are RX Prices Killing you?

Information provided by Mark, in Ga.
Are RX Prices Killing you?
This is free and you can print your own card online. The companies accept it without question so, it's simple. It is easy to look up any of your drugs to see the savings...most pharmacies take this card and they give you a list to choose from as well. Here's the link: http://distinctbenefitsolutions.com/
Once you click the link. Click "Print your free pharmacy card and start saving today". Fill in the four "field" lines and submit. Your card will appear instantly for you to print. The same page in which you fill out the "field box" has a box you may click below it "Drug Prices" which will give you the pricing of all your drugs and your choice of pharmacy. The savings are slightly different for each pharmacy.
I do not have drug coverage on my healthcare so; I have been using this card for sometime now. I find my drug costs to be considerably cheaper with this card than with my Walgreens Discount Savings Club card or any other card I have for example... Ambien generic cost with Walgreens drug card is approx $39.00 and with this card it's $12.00.
============================================
| Reactions: |
Teva to Present New Data on Its Innovative Therapies for Multiple Sclerosis at the Upcoming 2009 American Academy of Neurology Annual Meeting
Teva to Present New Data on Its Innovative Therapies for Multiple Sclerosis and Parkinson's Disease at the Upcoming 2009 American Academy of Neurology Annual Meeting
JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) today announced that several new studies addressing the Company’s innovative central nervous system (CNS) portfolio will be presented at the 61st Annual American Academy of Neurology meeting in Seattle starting April 28, 2009.
Long-term COPAXONE® (glatiramer acetate injection) data include an analysis demonstrating neuroprotection in relapsing-remitting multiple sclerosis (RRMS) patients.
New information on the treatment of Parkinson’s disease (PD) with AZILECT® (rasagiline tablets) include endpoints from the ADAGIO study; data demonstrating selectivity of MAO-B inhibition at maximum recommended dosing and the affect of treatment on non-motor symptoms in patients with early disease.
============================================
| Reactions: |
Which Multiple Sclerosis Therapy are you Using?
What you like or dislike about it?
How long you have been using it?
Had you used any other FDA approved MS medication prior?
Are you or have you used LDN?
And what you feel about this (like the above questions)
You need not give your real name but if you want others to contact you, make sure to provide your email address abd name.
All replies to be left in the form of a comment using the link found just below
The information you provide, could help somebody else.
============================================
| Reactions: |
Exercise Reduces Leakage through the Blood Brain Barrier
(Ivanhoe Newswire) -- A recent study suggests physical exercise may strengthen the blood- brain barrier, limiting harmful materials from entering the brain.
In the study, 3-month-old male mice represented men in their 20s. A group of 25 mice were held five weeks with exercise wheels that were used regularly and given the human equivalent of one gram of methamphetamine. These mice were compared with 25 mice that were also injected with the meth but did not have access to exercise wheels.
After analyzing the results, researchers found the meth caused higher body temperatures as well as agitated and increased physical activity in all the mice. However, the non-active mice experienced increased oxidative stress, affecting the permeability of the blood-brain barrier. The active mice experienced no such results.
Results show how regular exercise may have yet another benefit -- delaying the formation of neurodegenerative diseases such as Alzheimer’s and Parkinson’s. Both diseases are connected with leakage through the blood-brain barrier.
SOURCE: Presented at the Experimental Biology meeting in New Orleans, April 22, 2009
============================================
| Reactions: |
Tuesday, April 21, 2009
A group of 12 proteins associated with pediatric multiple sclerosis (MS) have been discovered
SOURCE: Newswise
Newswise — A group of 12 proteins associated with pediatric multiple sclerosis (MS) have been discovered for the first time by a team of neurology and pathology researchers at Stony Brook University Medical Center. Led by Lauren Krupp, M.D., Director of the National Pediatric MS Center at SBUMC, the finding could lead to a new panel of diagnostic and prognostic markers in pediatric MS. Their study is reported in the April 2009 issue of the journal Multiple Sclerosis.
Multiple Sclerosis is an inflammatory autoimmune disease of the central nervous system (CNS) which usually affects young adults. It is the most disabling chronic disorder of this age group, affecting more than 400,000 in the United States. In some instances, children can be affected. Diagnosing MS in children and adolescents is difficult, and standard MS diagnostic tests such as cerebral spinal fluid (CSF) analysis and magnetic resonance imaging (MRI) are often unreliable.
“This is the first study of its kind in children with MS that has the potential to advance progress in the diagnosis and estimation of the prognosis of all individuals affected by this disease,” says Dr. Krupp, noting the potential of the method as an early disease-specific marker. ============================================
| Reactions: |
Glasgow LDN Conference
Glasgow LDN Conference 2009
The first European Low Dose Naltrexone Conference takes place at Glasgow University, 25th April, 2009
Full Details: Glasgow LDN Conference 2009
Thank you
============================================
| Reactions: |
My Fight with MS - an MS patients' (Stem cell Therapy) story
http://startelegram.typepad.com/my_fight_with_ms/
Leave a comment.
| Reactions: |
Childhood MS Under The Spotlight At Children's Hospital
The first major UK scientific study into multiple sclerosis (MS) in children was launched on Saturday (18 April) marking a significant step forward in the understanding of the debilitating condition.
The paediatric MS study led by Birmingham Children's Hospital will follow a group of children for five years and will cost around £400,000, jointly funded by the MS Society and Action Medical Research.
The project was unveiled at a paediatric MS study day, organised by the Society, which gave families of children with MS from across the UK the chance to find out from exerts the latest developments in MS research.
Continue reading article directly at the Medical News Today's website
Please leave comments here.Thank You
============================================
| Reactions: |
Stem Cell Treatment Gives Texas Sheriff With Multiple Sclerosis His Job Back
Posted 20 April, 2009
Stem Cell Therapy - Giving Life Back
Multiple Sclerosis had taken many things away from Jason Upshaw- his job at the Sheriff’s department, his ability to play with his kids, as well as his ability to walk. Jason had given up hope . Luckily for Jason, he found an article about Preston Walker, another law enforcement officer in Texas with MS. Preston Walker had gone to Costa Rica for a new stem cell treatment and therapy using Adult Stem Cells and had reported tremendous improvements.
Jason, 36, of Erath County, Texas contacted Preston Walker who gave the stem cell therapy a glowing review. Jason promptly contacted the stem cell treatment company in Costa Rica and arranged to go there for treatment.
In June, 2008, Jason went to Costa Rica with his mother to receive the Adult Stem Cells that would turn his life around.
READ FULL article found here: Adult Stem Cell Pundit
Jason hasn’t let the FDA stop him from spreading the wonders of adult stem cell therapy around. Jason is now speaking in front of groups and writes 25-50 emails a day to MS patients who are in similar straits to where Jason once was.
One of those MS patients is Robyn Gorrie who is in Costa Rica now (April 2009) receiving stem cell therapy for her condition. Jason wrote a very nice email to her-
I now play baseball with my boys in the back yard. I’d nearly given up on ever being able to do that again, much less get back in to the profession I love. Please feel free to contact me at any time. You can call anytime. Please know that you are in my prayers and I hope you get to go, it has truly changed my life.
Your friend,
Jason Upshaw”
You can read Jason’s full email to Robyn here
Other MS Patients Who Have Had Successful Stem Cell Treatment in Costa Rica:Holly Huber, Jennifer Blankenship and Dennis Trammell and Angie Adcox, Joey Quinn, and Juli Balli who all followed in the footsteps of Richard Humphries and Preston Walker.
Leave comments by clicking the comment link found below.
============================================
| Reactions: |


